ПРИВЛЕЧЕНИЕ КАПИТАЛА БИОТЕХНОЛОГИЧЕСКИМИ И ФАРМАЦЕВТИЧЕСКИМИ КОМПАНИЯМИ: ОСОБЕННОСТИ ЕВРОПЕЙСКОГО РЫНКА

Abstract

The pharmaceutical industry is one of the most competitive sectors in the European Union. With significant investment in research and development, this industry is a key asset for the European economy and a major source of growth and employment. This article examines methods of raising capital for biotech and pharmaceutical companies. This paper also describes the impact of the COVID-19 pandemic on the biotechnology and pharmaceutical markets, identifies new trends in its development, as well as priority areas. Spread of the corona virus COVID-19 has created a multi-billion dollar market in the world and the EU in particular for vaccines needed to prevent the spread of the pandemic, rebuild the economy and begin the transition to a new paradigm of the growth. Particularly noteworthy there are the issues of raising capital through an initial public offering of securities — Initial Public Offering (IPO). At the beginning of the last decade, IPO markets were not receptive to biotech companies, but already in 2013 the situation changed dramatically. The increasing availability of private capital is making it more affordable to raise funds through IPOs, especially for the biotech and pharmaceutical industries.